NNW Headlines
Save 20% on Press Releases and More with NNW Prime! Click to View Details
Home » NewsRoom » NewsRoom Articles
TuesdayMar 13, 2018 7:30 pm

Can-Fite BioPharma Ltd. (NYSE: CANF) Starts Presentation at 30th Annual ROTH Conference

Can-Fite BioPharma (NYSE: CANF) is an advanced clinical stage drug development company with a platform technology that is intended to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. Piclidenoson, Can-Fite's lead drug candidate, is currently in a phase 3 trial for rheumatoid arthritis and is expected to enter a phase 3 trial for psoriasis during 2018. The company’s liver cancer drug, Namodenoson, is in phase 2 trials for the most common form of liver cancer, hepatocellular carcinoma (“HCC”), and for the treatment of non-alcoholic steatohepatitis (“NASH”). Namodenoson has been granted Orphan Drug Designation in the…

Continue Reading

TuesdayMar 13, 2018 7:30 pm

Applied DNA Sciences, Inc. (NASDAQ: APDN) Starts Presentation at 30th Annual ROTH Conference

Applied DNA Sciences (NASDAQ: APDN) provides molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The company’s proprietary DNA-based “CertainT™” platform can be used to identify, tag, test and track products to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All…

Continue Reading

TuesdayMar 13, 2018 7:30 pm

CV Sciences, Inc. (CVSI) Starts Presentation at 30th Annual ROTH Conference

CV Sciences (OTC: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences has primary offices and facilities in San Diego, California and Las Vegas, Nevada. The company also operates its own PlusCBD Oil™ brand. For more information, visit the company’s website at www.cvsciences.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach…

Continue Reading

TuesdayMar 13, 2018 7:30 pm

TheStreet, Inc. (NASDAQ: TST) Starts Presentation at 30th Annual ROTH Conference

TheStreet (NASDAQ: TST) is an independent digital financial media company delivering business and financial news, investing ideas and analysis to personal and institutional investors throughout the world. The company's business and personal finance brands include: TheStreet, RealMoney, RealMoney Pro, Action Alerts PLUS and MainStreet. The Deal is the company's institutional business, offering intraday coverage of mergers and acquisitions and all other changes in corporate control and offering director and officer profiles through the BoardEx product. RateWatch is the company's business unit, providing rate and fee data from banks and credit unions across the United States for a broad array of…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

Zedge, Inc. (NYSE: ZDGE) Starts Presentation at 30th Annual ROTH Conference

Zedge (NYSE: ZDGE) is a content platform and a world leader in smartphone personalization. The company has more than 288 million app installs and 33 million monthly active users. Users utilize Zedge to make their smartphones more personal, expressing their emotions, tastes and interests through wallpapers, icons, widgets, ringtones and more. The Zedge platform allows brands, artists and creators to share their smartphone personalization content with fans in order to extend their reach, reinforce their message and gain valuable insight into the ways customers interact with their content. For more information, visit the company’s website at www.corp.zedge.net. About NetworkNewsWire NetworkNewsWire…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Starts Presentation at 30th Annual ROTH Conference

Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmaceutical products to treat serious neuropsychiatric conditions and focused on improving biodefense through developing potential medical counter-measures. The company’s lead product candidate, Tonmya, or TNX-102 SL, is in phase 3 development as a bedtime treatment for PTSD and is also being developed as a bedtime treatment for agitation in Alzheimer’s patients. Tonmya has undergone a pre-IND (Investigational New Drug) meeting with the FDA, and the company’s TNX-601 (tianeptine oxalate) is in the pre-IND application stage for daytime dosing to treat PTSD. The company’s lead…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

Ocean Power Technologies, Inc. (NASDAQ: OPTT) Starts Presentation at 30th Annual ROTH Conference

Ocean Power Technologies (NASDAQ: OPTT) aims to change the world through lasting, pioneering and cost-effective ocean energy solutions. The company’s PB3 PowerBuoy utilizes ocean waves to deliver clean, reliable and persistent electric power as well as real-time communications for remote offshore applications in markets like oil and gas, defense, security, ocean observing and communications. Ocean Power Technologies is headquartered in New Jersey. For more information, visit the company’s website at www.oceanpowertechnologies.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

CohBar, Inc. (CWBR) Starts Presentation at 30th Annual ROTH Conference

CohBar (OTCQX: CWBR) is a biotech company engaged in the research and development of mitochondria-based therapeutics (“MBTs”) to treat various diseases associated with aging and metabolic dysfunction. MBTs originate from a discovery made by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts primarily focus on the development of these mitochondrial-derived peptides (“MDPs”) into clinically applicable MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including obesity, nonalcoholic steatohepatitis (“NASH”), Type 2 diabetes, cancer,…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

Boxlight Corp. (NASDAQ: BOXL) Starts Presentation at 30th Annual ROTH Conference

Boxlight (NASDAQ: BOXL) provides various technology and STEM solutions for the worldwide education market. The company offers educators products suitable for a modern classroom, resulting in improved student engagement and positive learning outcomes. Boxlight develops, sells and services its integrated, interactive solution suite of software, classroom technologies, professional development, and support services. The company also provides educators with thousands of free lesson plans and activities via MimioConnect®. For more information, visit the company’s website at www.boxlight.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to…

Continue Reading

TuesdayMar 13, 2018 7:00 pm

Altimmune, Inc. (NASDAQ: ALT) Starts Presentation at 30th Annual ROTH Conference

Altimmune (NASDAQ: ALT) is a clinical-stage biotechnology company that designs and develops immunotherapeutic products. The company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company’s product pipeline includes NasoVAX, a phase 2 seasonal influenza vaccine candidate, and HepTcell, a phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. Additionally, Altimmune has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. For more information,…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000

NetworkNewsWire

1108 Lavaca St
Suite 110-NNW
Austin, TX 78701
(512) 354-7000

NetworkNewsWire is powered by IBNAi

Copyright . NetworkNewsWire® / 1108 Lavaca St Suite 110-NNW Austin, TX 78701 (512) 354-7000 / Disclaimers